Delving into the Latest Updates on TQB-3473 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

TQB 3473

Target

Syk

Action

inhibitors

Mechanism

Syk inhibitors(Spleen tyrosine kinase inhibitors)

Therapeutic Areas

Immune System DiseasesHemic and Lymphatic Diseases

Active Indication

Purpura, Thrombocytopenic, Idiopathic

Inactive Indication

Chronic Lymphocytic LeukemiaRefractory Hematologic MalignancySmall Lymphocytic Lymphoma

Originator Organization

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Active Organization

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Inactive Organization-

License Organization-

Drug Highest PhasePhase 3

First Approval Date-

Regulation-

Login to view timeline

This is a randomized, double-blind, placebo-controlled Phase III clinical study designed to demonstrate that TQB3473 tablets significantly improve the sustained response rate compared to placebo in adult patients with chronic ITP who have previously received standard corticosteroid therapy and have failed or relapsed after at least one standard ITP treatment.
The study consists of a treatment period and a safety follow-up period.

Start Date01 May 2025

Sponsor / Collaborator

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

ChiCTR2200056806

/ SuspendedPhase 1IIT

Phase I trial to evaluate the tolerability and pharmacokinetics of TQB3473 tablets in adult subjects with persistent or chronic primary immune thrombocytopenia (ITP) - Phase I trial of TQB3473 tablets in adult subjects with persistent or chronic primary immune thrombocytopenia (ITP)

Start Date15 Mar 2022

Sponsor / Collaborator-

NCT04412577

/ Unknown statusPhase 1

A Phase I, Open-label, Dose Escalation and Expansion Study to Evaluate the Tolerance, Efficacy and Pharmacokinetics of TQB3473 Tablets

This is a study to evaluate the maximum tolerated dose (MTD), occurrence of all adverse events (AE) and serious adverse events (SAE) , pharmacokinetic parameters and antitumor effect of TQB3473 tablets in Chinese adult patients with Relapsed or refractory hematological malignancies.

Start Date12 Oct 2020

Sponsor / Collaborator

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

100 Clinical Results associated with TQB-3473

Login to view more data

100 Translational Medicine associated with TQB-3473

Login to view more data

100 Patents (Medical) associated with TQB-3473

Login to view more data

100 Deals associated with TQB-3473

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Purpura, Thrombocytopenic, Idiopathic	Phase 3	China	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	21 Apr 2025
Refractory Hematologic Malignancy	Phase 1	China	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	12 Oct 2020
Chronic Lymphocytic Leukemia	Phase 1	China	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	10 Sep 2020
Small Lymphocytic Lymphoma	Phase 1	China	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	10 Sep 2020

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ASH2024 Manual	Phase 1	Purpura, Thrombocytopenic, Idiopathic	36	TQB3473 400mg QD	jsiehtelma(ixrcklfcdy) = hdeyrbasqs zhljqkjzkn (wdgikonctd ) View more	Positive	09 Dec 2024
				TQB3473 600mg QD	jsiehtelma(ixrcklfcdy) = ojdcoccrxv zhljqkjzkn (wdgikonctd ) View more